A chronic autoimmune disease that affects the neuromuscular junction and produces serious weakness of voluntary muscles

Explore the Biological Bases of Behavior Test. Prepare with engaging flashcards and multiple choice questions, each featuring explanations. Start practicing today!

Multiple Choice

A chronic autoimmune disease that affects the neuromuscular junction and produces serious weakness of voluntary muscles

At the neuromuscular junction, communication between nerve and muscle can be disrupted when the immune system mistakenly targets the sites of communication. In this condition, antibodies attack the acetylcholine receptors (or related proteins) at the motor end plate, reducing the muscle’s ability to respond to nerve signals. With fewer functioning receptors, the transmission of the nerve impulse becomes unreliable, especially after repeated activity. This creates a pattern of weakness that grows with use and improves with rest, which is why it’s described as fatigable weakness. The disease is chronic and autoimmune, often involving thymic abnormalities, and management focuses on increasing acetylcholine effects at the NMJ (for example, with acetylcholinesterase inhibitors), modulating the immune response, and sometimes removing the thymus. This explanation fits because the hallmark is autoimmune disruption of the neuromuscular junction leading to fluctuating, voluntary muscle weakness. Other conditions differ in their primary targets: amyotrophic lateral sclerosis involves degeneration of motor neurons themselves with progressive, non-fluctuating weakness and muscle wasting; multiple sclerosis centers on autoimmune damage to the central nervous system’s myelin; Parkinson’s disease stems from loss of dopaminergic neurons in the brain, causing tremor, rigidity, and bradykinesia rather than NMJ transmission failure.

At the neuromuscular junction, communication between nerve and muscle can be disrupted when the immune system mistakenly targets the sites of communication. In this condition, antibodies attack the acetylcholine receptors (or related proteins) at the motor end plate, reducing the muscle’s ability to respond to nerve signals. With fewer functioning receptors, the transmission of the nerve impulse becomes unreliable, especially after repeated activity. This creates a pattern of weakness that grows with use and improves with rest, which is why it’s described as fatigable weakness. The disease is chronic and autoimmune, often involving thymic abnormalities, and management focuses on increasing acetylcholine effects at the NMJ (for example, with acetylcholinesterase inhibitors), modulating the immune response, and sometimes removing the thymus.

This explanation fits because the hallmark is autoimmune disruption of the neuromuscular junction leading to fluctuating, voluntary muscle weakness. Other conditions differ in their primary targets: amyotrophic lateral sclerosis involves degeneration of motor neurons themselves with progressive, non-fluctuating weakness and muscle wasting; multiple sclerosis centers on autoimmune damage to the central nervous system’s myelin; Parkinson’s disease stems from loss of dopaminergic neurons in the brain, causing tremor, rigidity, and bradykinesia rather than NMJ transmission failure.

More practice questions